• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

通过G4筛选和生物信息学分析研究GPR137C作为前列腺癌进展有前景的新型标志物。

Investigation of GPR137C as a promising novel marker for the progression of prostate cancer through G4 screen and bioinformatics analyses.

作者信息

Hou Yue, Lu Haowen, Chen Saisai, Mao Likai, Huang Xuan, Xu Feng, Shu Chuanjun

机构信息

Military Medical Innovation Center, Fourth Military Medical University, Xi'an, China.

Department of Urology, Affiliated Zhongda Hospital of Southeast University, Nanjing, Jiangsu, China.

出版信息

Front Immunol. 2025 May 30;16:1576835. doi: 10.3389/fimmu.2025.1576835. eCollection 2025.

DOI:10.3389/fimmu.2025.1576835
PMID:40519905
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12162501/
Abstract

INTRODUCTION

Prostate cancer (PCa) remains the fifth leading cause of male cancer mortality, necessitating novel biomarkers and therapeutic targets.

METHODS

Through BG4 ChIP-seq profiling in PCa cells, we identified promoter G-quadruplex (G4) structures in prognosis-associated genes, with GPR137C exhibiting a functional G4 in its promoter.

RESULTS

This G4 structure facilitates promoter hypomethylation to activate GPR137C transcription. Moreover, GPR137C promotes tumor microenvironment remodeling by enhancing immune cell infiltration, thereby driving PCa progression.

DISSCUSSION

This study establishes promoter G4s as epigenetic regulators in PCa while proposing GPR137C as both a prognostic biomarker and a therapeutic nexus for GPCR-targeted drug development.

摘要

引言

前列腺癌（PCa）仍是男性癌症死亡的第五大主要原因，因此需要新的生物标志物和治疗靶点。

方法

通过对前列腺癌细胞进行BG4染色质免疫沉淀测序（ChIP-seq）分析，我们在预后相关基因中鉴定出启动子G-四链体（G4）结构，其中GPR137C在其启动子中表现出功能性G4。

结果

这种G4结构促进启动子低甲基化以激活GPR137C转录。此外，GPR137C通过增强免疫细胞浸润促进肿瘤微环境重塑，从而推动前列腺癌进展。

讨论

本研究将启动子G4确立为前列腺癌中的表观遗传调节因子，同时提出GPR137C作为预后生物标志物以及用于GPCR靶向药物开发的治疗关联靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddf3/12162501/291779b59be3/fimmu-16-1576835-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddf3/12162501/0fc10c1c5cad/fimmu-16-1576835-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddf3/12162501/2de22a2f444b/fimmu-16-1576835-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddf3/12162501/b24e3e95d7e4/fimmu-16-1576835-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddf3/12162501/a56fd1934d62/fimmu-16-1576835-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddf3/12162501/ec1ca8696ed8/fimmu-16-1576835-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddf3/12162501/291779b59be3/fimmu-16-1576835-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddf3/12162501/0fc10c1c5cad/fimmu-16-1576835-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddf3/12162501/2de22a2f444b/fimmu-16-1576835-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddf3/12162501/b24e3e95d7e4/fimmu-16-1576835-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddf3/12162501/a56fd1934d62/fimmu-16-1576835-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddf3/12162501/ec1ca8696ed8/fimmu-16-1576835-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddf3/12162501/291779b59be3/fimmu-16-1576835-g006.jpg

相似文献

1
Investigation of GPR137C as a promising novel marker for the progression of prostate cancer through G4 screen and bioinformatics analyses.通过G4筛选和生物信息学分析研究GPR137C作为前列腺癌进展有前景的新型标志物。
Front Immunol. 2025 May 30;16:1576835. doi: 10.3389/fimmu.2025.1576835. eCollection 2025.
2
Epigenetic regulation of EFEMP1 in prostate cancer: biological relevance and clinical potential.前列腺癌中EFEMP1的表观遗传调控：生物学相关性及临床潜力
J Cell Mol Med. 2014 Nov;18(11):2287-97. doi: 10.1111/jcmm.12394. Epub 2014 Sep 11.
3
Integrated single-cell transcriptomic analyses identify a novel lineage plasticity-related cancer cell type involved in prostate cancer progression.整合单细胞转录组分析鉴定出一种新型与谱系可塑性相关的癌症细胞类型，该细胞类型与前列腺癌进展有关。
EBioMedicine. 2024 Nov;109:105398. doi: 10.1016/j.ebiom.2024.105398. Epub 2024 Oct 16.
4
Random forest-based modelling to detect biomarkers for prostate cancer progression.基于随机森林的前列腺癌进展生物标志物检测模型。
Clin Epigenetics. 2019 Oct 22;11(1):148. doi: 10.1186/s13148-019-0736-8.
5
Exploring targets of TET2-mediated methylation reprogramming as potential discriminators of prostate cancer progression.探索 TET2 介导的甲基化重编程的靶点作为前列腺癌进展的潜在鉴别标志物。
Clin Epigenetics. 2019 Mar 27;11(1):54. doi: 10.1186/s13148-019-0651-z.
6
Unveiling the NEFH+ malignant cell subtype: Insights from single-cell RNA sequencing in prostate cancer progression and tumor microenvironment interactions.揭示NEFH+恶性细胞亚型：前列腺癌进展和肿瘤微环境相互作用的单细胞RNA测序见解
Front Immunol. 2024 Dec 20;15:1517679. doi: 10.3389/fimmu.2024.1517679. eCollection 2024.
7
Epigenetic disruption of miR-130a promotes prostate cancer by targeting SEC23B and DEPDC1.miR-130a的表观遗传破坏通过靶向SEC23B和DEPDC1促进前列腺癌。
Cancer Lett. 2017 Jan 28;385:150-159. doi: 10.1016/j.canlet.2016.10.028. Epub 2016 Oct 27.
8
Diagnosis and prognosis potential of four gene promoter hypermethylation in prostate cancer.四种基因启动子甲基化在前列腺癌中的诊断和预后潜力。
Cell Biol Int. 2021 Jan;45(1):117-126. doi: 10.1002/cbin.11474. Epub 2020 Oct 8.
9
Comparative analysis of epi-miRNA expression levels in local/locally advanced and metastatic prostate cancer patients.局部/局部晚期和转移性前列腺癌患者中 epi-miRNA 表达水平的比较分析。
Gene. 2020 Oct 20;758:144963. doi: 10.1016/j.gene.2020.144963. Epub 2020 Jul 17.
10
GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture.GBX2 甲基化是一种新的预后生物标志物，可改善对非导管内癌和筛状结构的前列腺癌患者生化复发的预测。
Eur Urol Oncol. 2019 May;2(3):231-238. doi: 10.1016/j.euo.2018.08.003. Epub 2018 Sep 1.

本文引用的文献

1
The application of emerging immunotherapy in the treatment of prostate cancer: progress, dilemma and promise.新兴免疫疗法在前列腺癌治疗中的应用：进展、困境与前景。
Front Immunol. 2025 Mar 12;16:1544882. doi: 10.3389/fimmu.2025.1544882. eCollection 2025.
2
Association of composite dietary antioxidant index with high risk of prostate cancer in middle-aged and elderly men: insights from NHANES.中老年男性复合膳食抗氧化指数与前列腺癌高风险的关联：来自美国国家健康与营养检查调查（NHANES）的见解
Front Immunol. 2025 Feb 18;16:1530174. doi: 10.3389/fimmu.2025.1530174. eCollection 2025.
3
Comparative Toxicogenomics Database's 20th anniversary: update 2025.
比较毒理基因组学数据库成立20周年：2025年更新
Nucleic Acids Res. 2025 Jan 6;53(D1):D1328-D1334. doi: 10.1093/nar/gkae883.
4
Androgen production, uptake, and conversion (APUC) genes define prostate cancer patients with distinct clinical outcomes.雄激素生成、摄取和转化（APUC）基因可定义具有不同临床结局的前列腺癌患者。
JCI Insight. 2024 Oct 22;9(20):e183158. doi: 10.1172/jci.insight.183158.
5
Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial.雄激素受体通路抑制剂和紫杉烷类药物治疗转移性前列腺癌：一项基于结局适应性的随机平台试验。
Nat Med. 2024 Nov;30(11):3291-3302. doi: 10.1038/s41591-024-03204-2. Epub 2024 Aug 20.
6
Accurate structure prediction of biomolecular interactions with AlphaFold 3.利用 AlphaFold 3 进行生物分子相互作用的精确结构预测。
Nature. 2024 Jun;630(8016):493-500. doi: 10.1038/s41586-024-07487-w. Epub 2024 May 8.
7
SwissDock 2024: major enhancements for small-molecule docking with Attracting Cavities and AutoDock Vina.SwissDock 2024：小分子对接的重大增强，具有吸引腔和 AutoDock Vina。
Nucleic Acids Res. 2024 Jul 5;52(W1):W324-W332. doi: 10.1093/nar/gkae300.
8
Deorphanization of G Protein Coupled Receptors: A Historical Perspective.G 蛋白偶联受体的去孤儿化：历史透视。
Mol Pharmacol. 2024 May 17;105(6):374-385. doi: 10.1124/molpharm.124.000900.
9
Orphan G protein-coupled receptors: the ongoing search for a home.孤儿G蛋白偶联受体：仍在寻找归属
Front Pharmacol. 2024 Feb 29;15:1349097. doi: 10.3389/fphar.2024.1349097. eCollection 2024.
10
Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration.晚期前列腺癌中雄激素受体改变的临床意义：一项多机构合作研究
Prostate Cancer Prostatic Dis. 2024 Feb 22. doi: 10.1038/s41391-024-00805-3.